Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Cancer Surviv ; 13(4): 547-557, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31250352

RESUMEN

PURPOSE: Few studies have compared follow-up-care models for adult survivors of childhood cancer (ASCCs), though choice of model could impact medical test adherence, and health-related quality of life (QOL). This study compared two follow-up-care models, cancer-center-based versus community-based, for ASCCs in Alberta, Canada, to determine which model would demonstrate greater ASCC adherence to guideline-recommended medical screening tests for late effects, QOL, physical symptoms, and adherence to yearly follow-up. METHODS: ASCC discharged to a community model (over 15 years) and those with comparable birth years (1973-1993) currently followed in a cancer center model were recruited via direct contact or multimedia campaign. Chart review identified chemotherapeutic and radiation exposures, and required medical late effect screening tests. ASCCs also completed questionnaires assessing QOL, physical symptoms, and follow-up behavior. RESULTS: One hundred fifty-six survivors participated (community (n = 86); cancer center (n = 70)). Primary analysis indicated that cancer center ASCCs guideline-recommended total test adherence percentage (Mdn = 85.4%) was significantly higher than the community model (Mdn = 29.2%, U = 3996.50, p < 0.0001). There was no significant difference in QOL for cancer center ASCCs (M = 83.85, SD = 20.55 versus M = 77.50, SD = 23.94; t (154) = 1.77, p = 0.078) compared to community-based ASCCs. Cancer center-based ASCCs endorsed from 0.4-7.1% fewer physical symptom clusters, and higher adherence to follow-up behavior in comparisons using effect sizes without p values. CONCLUSION: This study highlights the cancer center model's superiority for adherence to exposure-based medical late effect screening guidelines, cancer-specific follow-up behaviors, and the reporting of fewer physical complaints in ASCCs. IMPLICATIONS FOR CANCER SURVIVORS: ASCCs followed in a cancer center model likely benefit from earlier late-effects detection and opportunities for early intervention.


Asunto(s)
Cuidados Posteriores/organización & administración , Supervivientes de Cáncer , Modelos Organizacionales , Neoplasias/terapia , Adolescente , Adulto , Cuidados Posteriores/normas , Canadá/epidemiología , Supervivientes de Cáncer/estadística & datos numéricos , Niño , Preescolar , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/epidemiología , Neoplasias/patología , Cooperación del Paciente/estadística & datos numéricos , Calidad de Vida , Encuestas y Cuestionarios
2.
J Thromb Haemost ; 6(4): 589-94, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18194413

RESUMEN

BACKGROUND: Deep vein thrombosis (DVT) is a complication of treatment of acute lymphoblastic leukemia (ALL) in children but little is known about the long-term outcomes of these DVT. OBJECTIVE: To determine the incidence of post-thrombotic syndrome (PTS) in (i) children with ALL diagnosed with asymptomatic DVT using radiographic testing and (ii) an unselected group of ALL survivors. METHODS: Cross-sectional study in two populations. Group I comprised children in the Prophylactic Antithrombin Replacement in Kids with ALL treated with L-Asparaginase (PARKAA) study diagnosed with DVT by radiographic tests. Group II consisted of non-selected childhood ALL survivors <21 years. PTS was assessed using a standardized scoring sheet. RESULTS: Group I: 13 PARKAA patients (median age 12 years) were assessed, and 7 had PTS (54%; 95% CI, 25-81). All patients had collaterals, three also had increased arm circumference. Group II: 41 patients (median age 13 years) with a history of ALL were enrolled, and 10 had PTS (24%; 95% CI, 11-38). All patients had collaterals; five also had increased arm circumference. CONCLUSION: There is a high incidence of PTS in survivors of childhood ALL with radiographically diagnosed asymptomatic DVT. A significant proportion of ALL survivors develop PTS, indicating previously undiagnosed DVT.


Asunto(s)
Síndrome Postrombótico/epidemiología , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Trombosis de la Vena/complicaciones , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Deficiencia de Antitrombina III/inducido químicamente , Brazo/irrigación sanguínea , Brazo/patología , Asparaginasa/administración & dosificación , Asparaginasa/efectos adversos , Cateterismo Venoso Central/efectos adversos , Niño , Preescolar , Ensayos Clínicos Fase II como Asunto/estadística & datos numéricos , Circulación Colateral , Estudios Transversales , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangre , Prevalencia , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Sobrevivientes , Trombofilia/inducido químicamente , Trombosis de la Vena/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA